Sep 2, 2026 04:01PM
Sep 2, 2026 04:01PM
Sep 1, 2026 04:06PM
Sep 1, 2026 04:05PM
Aug 20, 2026 06:56AM
Aug 20, 2026 06:50AM
Aug 20, 2026 05:04AM Citi raises Ultragenyx price target to $58 after FDA approval
Aug 19, 2026 05:21PM
Aug 19, 2026 05:21PM
Aug 4, 2026 04:05PM
Jun 23, 2026 08:00AM
Jun 23, 2026 08:00AM
May 5, 2026 04:01PM
Apr 2, 2026 12:00PM Morgan Stanley on Ultragenyx Pharma (RARE): BLA submission acceptance removes key overhang
Apr 2, 2026 10:46AM
Apr 2, 2026 08:31AM
Apr 2, 2026 08:30AM
Mar 30, 2026 08:32AM
Mar 30, 2026 08:30AM
Feb 23, 2026 08:30AM
Feb 23, 2026 08:30AM Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
Feb 18, 2026 06:44AM
Feb 12, 2026 04:01PM
Feb 3, 2026 06:44AM
Jan 30, 2026 08:31AM
Jan 30, 2026 08:30AM
Jan 12, 2026 07:31AM
Jan 12, 2026 07:30AM Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
Dec 30, 2025 04:06PM
Dec 30, 2025 04:05PM
Dec 30, 2025 04:58AM
Dec 30, 2025 02:03AM
Dec 29, 2025 01:50PM
Dec 29, 2025 08:30AM
Dec 29, 2025 08:30AM Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
Nov 4, 2025 04:05PM
Oct 30, 2025 08:00AM
Sep 8, 2025 04:05PM
Sep 8, 2025 04:05PM
Aug 18, 2025 08:06AM
Aug 18, 2025 08:00AM
Aug 5, 2025 04:01PM Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update
Jul 31, 2025 04:05PM
Jul 31, 2025 04:05PM
Jul 14, 2025 08:01AM
Jul 14, 2025 08:00AM
Jul 11, 2025 05:05PM
Jul 11, 2025 04:30PM
Jul 11, 2025 04:30PM Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
Jul 9, 2025 04:05PM

330,192 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All